Single molecule sequencing method
By using multi-color sequencing methods and optical signal imaging technology in single-molecule sequencing, the problems of sequencing error rate and read length limitation in the prior art are solved, and high-quality and short-term nucleic acid sequencing are achieved.
Patent Information
- Application Number
- PCT/CN2024/106448
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-30
- Filing Date
- 2024-07-19
- Publication Date
- 2024-12-05
AI Technical Summary
The existing single-molecule sequencing methods have limitations in terms of sequencing error rate and read length, making it difficult to achieve high-quality and short-term sequencing at the same time.
Using multi-color sequencing method, the polymerization reaction of four nucleotides carrying different optical detection marks and nucleic acid template-primer complexes on solid phase carriers is achieved, combined with polymerase catalysis, single-base extension is achieved, and optical signals are passed Chemical cleavage technology for imaging and excision markers to gradually determine the nucleic acid sequence.
It significantly reduces the sequencing error rate, improves the sequencing quality, and shortens the sequencing time while achieving longer read lengths.
Smart Images

Figure CN2024106448_05122024_PF_FP_ABST
Abstract
Description
Single-molecule sequencing methods Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a single molecule sequencing method. Background Art
[0002] Compared with second-generation high-throughput sequencing (NGS), single-molecule sequencing directly sequences the labeled nucleic acid molecules to be tested by fixing them on the surface of a solid phase carrier. There is no need to perform PCR amplification on the nucleic acid molecules to be tested, thereby simplifying the construction process of the sequencing library and avoiding errors caused by nucleic acid molecule amplification.
[0003] During the single-molecule sequencing process, according to the number of nucleotides or their analogs added in each polymerization reaction, single-molecule sequencing can be divided into monochrome sequencing and multi-color sequencing, wherein multi-color sequencing can be divided into dual-color sequencing and four-color sequencing. For monochrome sequencing, four single-base extensions are performed respectively by sequentially adding 4 kinds of optically detectable labeled nucleotides (G, A, T, C), and in each extension reaction, the signal generated by the optically detectable label of a certain / some visual field is collected, and the type of nucleotide introduced at the site is determined by the signal generated by each site; then, the optically detectable label is removed and the next round of reaction is performed. In this way, it is repeated multiple times or multiple rounds to obtain a group of signal images at different moments of the corresponding same visual field (each time / round reaction), and then the information of the group of images is superimposed in the order in which the reaction occurs to determine the sequence of the nucleic acid molecule to be tested. Unlike monochrome sequencing, multi-color sequencing adds multiple nucleotides such as two or four at each single base extension, that is, each single base extension realizes the introduction of at least two nucleotides. Taking dual-color sequencing as an example, each base extension can complete the introduction of two nucleotides, and a round of sequencing can be completed by two base extensions. It can be seen that compared with single-color sequencing, the overall sequencing time of multi-color sequencing can be shortened, but the sequencing read length and sequencing error rate still have limitations.
[0004] Application Contents
[0005] In view of this, the present invention provides a single-molecule sequencing method. The single-molecule sequencing method provided by the present invention is conducive to reducing sequencing error rates, improving sequencing quality, and having longer sequencing read lengths while shortening sequencing time.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The present invention provides a single molecule sequencing method, comprising the following steps:
[0008] (i) providing a solid phase support, wherein the solid phase support comprises a plurality of sites, each of which is immobilized with a nucleic acid template-primer complex;
[0009] (ii) binding four nucleotides or their analogs carrying different optically detectable labels to the nucleic acid template-primer complex through a polymerization reaction to achieve single-base extension and obtain an extension product;
[0010] (iii) exciting the optical detection label to generate an optical signal, imaging the extension product, and obtaining an image;
[0011] (iv) removing the optical detection label on the extension product;
[0012] (v) replacing the nucleic acid template-primer complex with the extension product from which the optically detectable label has been removed, and repeating the above steps (ii) to (iv) one or more times to determine the template nucleic acid sequence.
[0013] In some embodiments of the present invention, a mixture solution of two or four nucleotides or their analogs carrying different optically detectable labels is contacted with the nucleic acid template-primer complex to allow the nucleotides or their analogs to bind to the nucleic acid template-primer complex.
[0014] In some embodiments of the present invention, the final concentrations of the four nucleotides in the sequencing method are 125 nmol / L to 1000 nmol / L, respectively.
[0015] In some embodiments of the present invention, the general formula of the nucleotide or its analogue in the above sequencing method is as shown in Formula 1:
[0016] Wherein, B is a base or its analogue, L1 and L2 are each independently a covalent bond or a covalent linking group, R1 is -OH or a phosphate group, R2 is H or a chemically cleavable group, R3 is H or -OR5, R5 is H or a chemically cleavable group, and R4 contains the optical detection label.
[0017] In some embodiments of the present invention, in the above sequencing method, the B is selected from adenine or its analogue, guanine or its analogue, cytosine or its analogue, thymine or its analogue or uracil or its analogue.
[0018] In some embodiments of the present invention, in step (ii) of the above sequencing method, B is selected from adenine or its analogue, cytosine or its analogue, thymine or its analogue, or uracil or its analogue, and the final concentration of the nucleotide or its analogue is 500 nmol / L to 1000 nmol / L; B is guanine or its analogue, and the final concentration of the nucleotide or its analogue is 125 nmol / L to 500 nmol / L.
[0019] In some embodiments of the present invention, in the above sequencing method, different nucleotides or analogs thereof carry different optical detection labels.
[0020] In some embodiments of the present invention, in the above sequencing method, the optical detection label includes one or more of Atto532, CY5, IF700, ROX, rhodamine dye, cyanine dye, coumarin dye or phycoerythrin.
[0021] In some embodiments of the present invention, in the above-mentioned sequencing method, when the nucleotide or its analogue is an adenine nucleotide or its analogue, the optical detection label of the nucleotide or its analogue is the Atto532; when the nucleotide or its analogue is a guanine nucleotide or its analogue, the optical detection label of the nucleotide or its analogue is the CY5; when the nucleotide or its analogue is a cytosine nucleotide or its analogue, the optical detection label of the nucleotide or its analogue is the IF700; when the nucleotide or its analogue is a thymine nucleotide or its analogue, the optical detection label of the nucleotide or its analogue is the ROX.
[0022] In some embodiments of the present invention, in the above sequencing method, in step (ii), a polymerase is used to bind four nucleotides or their analogs carrying optical detection labels to the nucleic acid template-primer complex to achieve single base extension; wherein the polymerase is a DNA polymerase and / or an RNA polymerase, and the final concentration of the polymerase is 0.005 mg / mL to 0.02 mg / mL.
[0023] In some embodiments of the present invention, in the above sequencing method, the enzyme includes one or more of: 9°N enzyme, Pfu, KOD1 and MMS2.
[0024] In some embodiments of the present invention, in the above sequencing method, in step (ii), the polymerization reaction is carried out at a pH of 8.0 to 9.0.
[0025] In some embodiments of the present invention, the optically detectable label is linked to the nucleotide or its analog via a chemically cleavable group, and in step (iv), the removal of the optically detectable label on the extension product is achieved using an excision reagent comprising an organic phosphine and a buffer.
[0026] In some embodiments of the present invention, in the above sequencing method, in step (iv), removing the optical detection label on the extension product is performed at a pH of 8.0 to 10.5 and a temperature of 39° C. to 65° C.
[0027] In some embodiments of the present invention, in the above sequencing method, the concentration of the organic phosphine is 10 mmol / L to 100 mmol / L; and / or the concentration of the buffer is 0.01 mol / L to 2 mol / L.
[0028] In some embodiments of the present invention, in the above sequencing method, the organic phosphine is selected from tris(3-hydroxypropyl)phosphine, tris(2-carboxyethyl)phosphine, trishydroxymethylphosphine, triphenylphosphine, and tris(2-hydroxyethyl)phosphine.
[0029] In some embodiments of the present invention, in step (iii), exciting the optical detection label to generate an optical signal comprises exposing the solid phase carrier to light, wherein the exposure time is 100 ms to 400 ms.
[0030] In some embodiments of the present invention, in the above sequencing method, the optical detection label includes a first optical detection label and a second optical detection label, and the excitation wavelengths of the first optical detection label and the second optical detection label differ by at least 50 nm.
[0031] In some embodiments of the present invention, in the above-mentioned sequencing method, the first optical detection label is a red light-excitable fluorescent group, and the exposure time of the red light-excitable group is 100ms to 400ms; the second optical detection label is a green light-excitable fluorescent group, and the exposure time of the green light-excitable group is 50ms to 100ms.
[0032] The sequencing method provided by the present invention has a lower sequencing error rate, helps to improve sequencing quality, and shortens sequencing time. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without any creative work.
[0034] in:
[0035] FIG1 is a graph showing the brightness results of dCTP-N3-IF700 and dGTP-N3-CY5 obtained at different exposure times using a 640 nm laser according to an embodiment of the present application;
[0036] FIG2 is a comparison diagram of a C fluorescence image obtained by single-color sequencing and a GC fluorescence image obtained by multi-color sequencing according to an embodiment of the present application;
[0037] FIG3 is a graph showing the effect of different exposure times on the 40-cycle read length distribution according to an embodiment of the present application;
[0038] FIG4 is a graph showing the effect of different exposure times on 50-cycle read length distribution according to an embodiment of the present application;
[0039] FIG5 is a statistical graph showing base excision efficiency of four-color sequencing under different concentrations of THPP treatment according to an embodiment of the present application;
[0040] FIG6 is a statistical graph of base excision efficiency in four-color sequencing using Tris buffer at different concentrations according to an embodiment of the present application;
[0041] FIG7 is a statistical graph of base excision efficiency of four-color sequencing under different pH conditions according to an embodiment of the present application;
[0042] FIG8 is a statistical graph of base excision efficiency of four-color sequencing under different temperature reactions according to an embodiment of the present application;
[0043] FIG9 is a 50-cycle sequencing read length distribution diagram according to an embodiment of the present application;
[0044] FIG10 shows the error rate distribution of 50-cycle four-color sequencing according to an embodiment of the present application. DETAILED DESCRIPTION
[0045] The following will be combined with the drawings in the embodiments of this application to clearly and completely describe the technical solutions in the embodiments of this application. Obviously, the embodiments described are only part of the embodiments of this application, not all of the embodiments. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of this application.
[0046] The present invention discloses a single molecule sequencing method.
[0047] It should be understood that the expression "one or more of" includes individually each of the items recited after the expression and various combinations of two or more of the recited items, unless otherwise apparent from the context and usage. The expression "and / or" in conjunction with three or more recited items should be understood to have the same meaning, unless otherwise apparent from the context.
[0048] The terms "comprising", "having" or "containing", including their grammatical synonyms, should generally be understood as open and non-restrictive, e.g., not excluding other unrecited elements or steps, unless otherwise specifically stated or understood from the context.
[0049] It should be understood that the order of steps or the order in which certain actions are performed are not important as long as the present invention remains operable. Additionally, two or more steps or actions may be performed simultaneously.
[0050] The use of any and all examples or exemplary language such as "for example" or "including" herein is merely for better illustration of the present invention and is not intended to limit the scope of the present invention. No language in this specification should be construed as indicating that any non-claimed element is essential to the practice of the present invention.
[0051] In addition, the numerical ranges and parameters used to define the present invention are approximate values. The relevant numerical values in the specific examples have been presented as accurately as possible. However, any numerical value inherently inevitably contains standard deviations due to individual testing methods. Therefore, unless otherwise expressly stated, all ranges, amounts, values, and percentages used in this disclosure should be understood to be modified by the word "about." As used herein, "about" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a specified value or range.
[0052] The terms "first," "second," "third," and "fourth" are used for descriptive purposes only, to distinguish objects such as positions, objects, etc. from one another, and should not be understood as indicating or implying relative importance or implicitly indicating the number of the technical features indicated. For example, without departing from the scope of the embodiments of the present application, "first" and "second" may be interchangeable, such as the first location may also be referred to as the second location, and correspondingly, the second location may be referred to as the first location. Thus, a feature defined as "first," "second," "third," or "fourth" may explicitly or implicitly include one or more of such features.
[0053] The term "sequencing," also known as "nucleic acid sequencing" or "gene sequencing," is interchangeable and refers to the determination of the types and order of bases or nucleotides (including nucleotide analogs) in a nucleic acid molecule. Sequencing involves the process of binding nucleotides to a template and collecting the corresponding signals emitted by the nucleotides (including analogs). Sequencing includes sequencing by synthesis (SBS) and / or sequencing by ligation (SBL), encompassing DNA sequencing and / or RNA sequencing.
[0054] Sequencing generally includes multiple rounds to realize the process of determining the type and arrangement order of multiple bases or nucleotides on the nucleic acid template. In the embodiment of the present application, each round of "process of determining the type and arrangement order of multiple bases or nucleotides on the nucleic acid template" is referred to as "one round of sequencing". "One round of sequencing" (cycle) is also called "sequencing round", which can be defined as a base extension of four nucleotides / bases. In other words, "one round of sequencing" can be defined as the determination of the base or nucleotide type at any specified position on the template. For sequencing platforms that realize sequencing based on polymerization or ligation reaction, one round of sequencing includes realizing that four nucleotides (including nucleotide analogs) are bound to the so-called nucleic acid template in a base complementary manner, and collecting the corresponding signal process emitted. Among them, for platforms that realize sequencing based on polymerization reaction, the reaction system includes reaction substrate nucleotides, polymerase and nucleic acid template, and a sequence (sequencing primer) is combined with the nucleic acid template. Based on the base pairing principle and the polymerization reaction principle, the added reaction substrate nucleotides are connected to the sequencing primer under the catalysis of the polymerase to realize the binding of the nucleotide to the specific position of the nucleic acid template. Generally, one round of sequencing may include one or more base extensions (repeat). For example, four nucleotides are added to the reaction system in sequence, and base extension and corresponding reaction signal collection are performed respectively, and one round of sequencing includes four base extensions. For another example, any combination of the four nucleotides is added to the reaction system, such as two-by-two combinations or one-by-three combinations, and base extension and corresponding reaction signal collection are performed for two combinations respectively, and one round of sequencing includes two base extensions. For another example, the four nucleotides are added to the reaction system at the same time for base extension and reaction signal collection, and one round of sequencing includes one base extension.
[0055] Nucleotides refer to the four natural nucleotides (e.g., dATP, dCTP, dGTP, and dTTP or ATP, CTP, GTP, and UTP) or their derivatives, and are sometimes directly represented by the bases they contain (A, T or U, C, and G). A person of ordinary skill in the art will know the nucleotide or base referred to by the expression according to the context.
[0056] The term "nucleic acid molecule" refers to a polymeric form of nucleotides of any length and may include ribonucleotides or their analogs, deoxyribonucleotides or their analogs, and mixtures of the above nucleotides or their analogs. The so-called nucleic acid molecules may refer to single-stranded polynucleotides or double-stranded polynucleotides. The nucleotides in the nucleic acid molecule may include naturally occurring nucleotides and their functionally alternative analogs. Examples of analogs are capable of hybridizing with nucleic acids in a sequence-specific manner or can be used as templates for the replication of a specific nucleotide sequence. Naturally occurring nucleotides typically have a backbone comprising a phosphodiester bond. Analog structures may have alternative backbone connections including any type known in the art. Naturally occurring nucleotides typically have deoxyribose (e.g., found in DNA) or ribose (e.g., found in RNA). Analog structures may have alternative sugar moieties including any type known in the art. Nucleotides may include natural bases or non-natural bases. The bases in natural DNA may include one or more of adenine, thymine, cytosine, and / or guanine, and the bases in natural RNA may include one or more of adenine, uracil, cytosine, and / or guanine. Nucleotides may also use any non-natural bases or base analogs, such as locked nucleic acids (LNAs) and bridged nucleic acids (BNAs).
[0057] The term "nucleic acid template" refers to a master nucleic acid molecule or a master nucleic acid molecule fragment that is bound to nucleotides or nucleotide analogs through multiple consecutive rounds of base extension. The so-called nucleic acid template can be the entire sequence of a nucleic acid molecule or a partial fragment of a nucleic acid molecule. The "nucleic acid template" referred to herein can be a nucleic acid fragment that serves as a template in an extension reaction for sequencing by synthesis. Because the bases added during the extension reaction satisfy the base pairing principle with the sequencing template, the sequence of the sequencing template can be determined by determining the base types added during each extension reaction. The sequence of the nucleic acid template herein may generally include, but is not limited to, at least one of the target molecule sequence, the UMI sequence, and the sample tag sequence, and is sometimes referred to herein as an "insert fragment" or "target molecule."
[0058] The term "primer", also known as "probe", refers to an oligonucleotide or nucleic acid molecule that can hybridize with a target sequence of interest. In an embodiment, a primer acts as a substrate onto which nucleotides can be polymerized by a polymerase. For example, a primer can be used as a starting point for DNA or RNA synthesis. For example, a sequencing primer can hybridize with a synthetic nucleic acid template strand to initiate the synthesis of a new strand complementary to the synthetic nucleic acid template strand. A primer can include any combination of nucleotides or their analogs. In some instances, a primer is a single-stranded oligonucleotide or polynucleotide.
[0059] In the examples of the present application, it should be understood that "XX or its analogues" include "XX" and "XX analogues", and illustratively: nucleotides or their analogues include nucleotides and nucleotide analogs, bases or their analogues include bases and base analogs, ribose groups or their analogues include ribose and ribose analogues, and deoxyribose groups or their analogues include deoxyribose and deoxyribose analogues.
[0060] The term "analog" or "functional analog" refers to a chemical compound that is structurally similar to another compound (the so-called "reference" compound) but has a different composition, such as the replacement of an atom by an atom of a different element, or the presence of a specific functional group, or the replacement of one functional group by another.
[0061] The term "FOV" (Field of View) refers to the field of view. During the solid substrate application process, an optical camera is used to perform multiple rounds of optical imaging (photographing) of a fixed area of the solid substrate. The area captured by the optical camera each time is called the FOV (field of view).
[0062] The following describes the single-molecule sequencing method using sequencing-by-synthesis as an example. The single-molecule sequencing method provided in the embodiments of the present application includes:
[0063] (i) providing a solid phase support, wherein the solid phase support comprises a plurality of sites, each of which is immobilized with a nucleic acid template-primer complex.
[0064] In this step, the solid phase carrier is understood to be a carrier or support for fixing nucleic acid molecules or nucleic acid templates. In some application examples, the solid phase carrier can also be called a solid phase substrate, a sequencing chip or a sequencing biochip. In one embodiment, the solid phase carrier is a substrate with an array of micropores, and the position of each micropore corresponds to a site. Exemplarily, the solid phase carrier is a nanowell array chip, which includes nanowells arranged in an array for fixing nucleic acid template-primer complexes, wherein the nanowells can also be called nanopores or micropores or holes. In the embodiments of the present application, the nanowells and nanopores referred to are interchangeable and refer to a nanoscale pore structure formed on the surface of the solid phase carrier. The shape of the nanowell or nanopore is not strictly limited and can be circular, elliptical, triangular, quadrilateral or other polygonal, or even has no specific shape. In some embodiments, the nanowell or nanopore is arranged in a shape with a cross section of a symmetrical figure. Exemplarily, the cross section of the nanowell or nanopore is circular or a regular polygon.
[0065] In one embodiment, the solid support is a planar substrate having a surface comprising a plurality of surface-treated locations, each corresponding to a site for immobilizing a nucleic acid template-primer complex. Surface treatment refers to forming reactive functional groups on the surface capable of binding to the nucleic acid template-primer complex. An example of this type of solid support is a random chip.
[0066] The solid phase carrier has multiple sites, and there is a certain distance between two adjacent sites, and the distance is large enough to enable the optical signals generated by the optical detection labels at the adjacent sites to be distinguished.
[0067] In the present embodiment, a nucleic acid template is fixed to the surface of the solid support, and the nucleic acid template is connected to the surface of the solid support. In one embodiment, a probe is connected to the surface of the solid support, and the probe is covalently bonded to the molecule / group on the surface of the solid support, and the nucleic acid template is connected to the surface of the solid support through the probe. Wherein, the probe is an oligonucleotide or nucleic acid molecule fragment that can hybridize with the target nucleic acid molecule of interest. In one embodiment, at least a portion of the probe is configured to hybridize with at least a portion of the 3' end of the nucleic acid template. In another embodiment, one end of the nucleic acid template is covalently bonded to the molecule / group on the surface of the solid support, thereby being connected to the surface of the solid support. In the embodiment of the present application, the probe and the nucleic acid template together form a nucleic acid template-primer complex.
[0068] In this embodiment, the solid phase carrier has multiple sites, and the nucleic acid template is fixed on the site of the solid phase carrier accordingly. According to the embodiments of the present application, ideally, each site is fixed with a nucleic acid template. In some unavoidable cases, there may be a very small number of sites without a fixed nucleic acid template or a site with two nucleic acid templates fixed. When the same site contains two different nucleic acid templates, the site generates two detectable signals in one round of sequencing. In order to improve the accuracy of sequencing, the sequencing signals of these sites are not counted, and the corresponding sequencing data are removed.
[0069] In some embodiments, the solid phase carrier contains a channel structure that can connect one end of the solid phase carrier to the other end. In this case, the solution and / or reagent containing the polymerization reaction in step (ii) and other solutions that need to be contacted with the solid phase carrier later can be brought into contact by flowing through the surface of the channel structure. In one embodiment, the channel structure on the surface of the solid phase carrier can be formed on the surface of the solid phase carrier by a method such as etching. By a method such as etching, the material in a part of the surface area of the solid phase carrier is removed so that a groove structure is formed in this part of the area. The groove structure leads from one end of the solid phase carrier to the other end of the solid phase carrier. The channel structure on the surface of the solid phase carrier can also be formed by covering the surface of a solid phase substrate with a certain thickness with a mask material layer, and the pattern of the mask material layer corresponds to the channel structure expected to be set on the surface of the solid phase carrier. For example, the mask material layer covers the area where the corresponding groove is located, and hollows out other areas outside the groove area, and then deposits material in the hollowed area of the mask material layer by a method such as chemical deposition, thereby forming a material layer with a channel structure on the surface of the solid phase carrier. The solid phase carrier and the material layer formed on its surface together constitute the solid phase carrier. It should be understood that the surface of the solid support may have one channel structure, or may have two or more channel structures, such as 4, 8, or 16 channel structures. Of course, the number of channel structures is not limited thereto. In some embodiments, the channel structure on the surface of the solid support is also called a Lane.
[0070] Exemplarily, the width of the channel structure is 5 to 15 mm, and the height is 50 μm to 200 μm. It should be understood that the width and height of the solid phase carrier can be arbitrarily combined within the above ranges without strict restrictions. Exemplarily, when the width of the solid phase carrier is 5 to 10 mm, the height of the solid phase carrier can be in the range of 50 μm to 100 μm, or in the range of 80 μm to 120 μm, or in the range of 100 μm to 150 μm, 120 μm to 180 μm, or in the range of 180 μm to 200 μm, etc.; of course, when the width of the solid phase carrier is 10 to 15 mm, similarly, the height of the solid phase carrier can be in the range of 50 μm to 100 μm, or in the range of 80 μm to 120 μm, or in the range of 100 μm to 150 μm, 120 μm to 180 μm, or in the range of 180 μm to 200 μm, etc.
[0071] (ii) Four nucleotides or their analogs carrying different optical detection labels are bound to the nucleic acid template-primer complex by polymerization reaction to achieve single base extension and obtain extension products.
[0072] In this step, under conditions suitable for the polymerization reaction, nucleotides or their analogs carrying different optical detection labels are added to the surface of the solid phase carrier, so that the nucleotides or their analogs pair with the nucleic acid template through the principle of base complementary pairing and bind to the nucleic acid template-primer complex.
[0073] In some embodiments, the final concentration of each nucleotide or its analogue is 125 nmol / L to 1000 nmol / L. It should be understood that the final concentration of nucleotides or their analogues referred to in the embodiments of the present application refers to the concentration of nucleotides or their analogues when the solution containing nucleotides or their analogues contacts the nucleic acid template-primer complex. Exemplarily, a reaction solution containing nucleotides or their analogues is passed through a solid phase carrier, and the concentration of nucleotides or their analogues in the reaction solution is the final concentration of nucleotides or their analogues. In one embodiment, this step is performed by pumping different reagents from different test kits, mixing the reagents to form a mixed solution, and flowing it into the surface of the solid phase carrier. At this time, the final concentration of nucleotides or their analogues should be the concentration of nucleotides or their analogues in the mixed solution. The final concentration of nucleotides or their analogues in the embodiments of the present application is set to 125 nmol / L to 1000 nmol / L in order to reduce the adsorption of nucleotides or their analogues in other areas outside the solid phase carrier surface site under polymerization reaction conditions, thereby reducing the non-specific adsorption formed thereby. The optical detection labels in the nucleotides or their analogs at the locations of these non-specific adsorptions are excited in step (iii) to generate optical signals, which increase the background noise in the image obtained, interfere with the recognition of the optical signals at the sites, and thus affect the accuracy of base recognition.
[0074] In the examples of the present application, the final concentration of each nucleotide or its analogue can be adjusted within the range of 125 nmol / L to 1000 nmol / L according to the type of nucleotide or its analogue, the concentration of polymerase in the reaction system, etc.
[0075] In some embodiments, a nucleotide or its analogue can be represented by the following general structure:
[0076] In Formula 1, B is a base or an analog thereof. In some embodiments, B is cytosine or a derivative thereof, thymine or a derivative thereof, adenine or a derivative thereof, guanine or a derivative thereof, hypoxanthine or a derivative thereof, deazaadenine or a derivative thereof, deazaguanine or a derivative thereof, deazahypoxanthine or a derivative thereof, 7-methylguanine or a derivative thereof, 5,6-dihydrouracil or a derivative thereof, 5-methylcytosine or a derivative thereof, or 5-hydroxymethylcytosine or a derivative thereof.
[0077] According to an embodiment of the present invention, B is divalent cytosine or its derivatives, divalent guanine and its derivatives, dimethyl pyrimidine or its derivatives, divalent thymine or its derivatives, divalent uracil or its derivatives, divalent hypoxanthine or its derivatives, divalent xanthine or its derivatives, divalent deazaadenine or its derivatives, divalent deazaguanine or its derivatives, divalent deazahypoxanthine or its derivatives, divalent 7-methylguanine or its derivatives, divalent 5,6-dihydrouracil or its derivatives, divalent 5-methylcytosine or its derivatives or divalent 5-hydroxymethylcytosine or its derivatives.
[0078] In Formula 1, L1 is used to connect B and the cleavable azide group, L2 is used to connect the cleavable azide group and R4, and L1 and L2 are each independently a covalent bond or a covalent linking group. Wherein, the cleavable azide group is bound to one side of the nucleotide or its analog base, and by forming a certain spatial conformation, it produces steric hindrance to the 3' hydroxyl site of ribose or deoxyribose, thereby blocking the activity of the site to undergo polymerization reaction with other nucleotides or nucleotide analogs, such as -O-CH(N3)-L2-R4. The reversible termination group can be removed (reduced to a hydroxyl group) by chemical reaction under appropriate conditions. Wherein, the appropriate conditions can be chemical reaction conditions that can induce the reversible termination group to be reduced to a hydroxyl group.
[0079] In some embodiments, L1 is an independent bond, or a substituted or unsubstituted C 1-8 Alkylene, or substituted or unsubstituted 2 to 8 membered heteroalkylene, or substituted or unsubstituted C 3-8 Cycloalkylene, or substituted or unsubstituted 3 to 8 membered heterocyclic alkylene, or substituted or unsubstituted C 6-8 Arylene.
[0080] For example, L1 may select the following structure:
[0081] Where g1 is an integer between 0 and 10, R L1 is NH or O; g1 is preferably 1, 4; or Where g2 is 0, 1, 2, 3, 4 or 5, R L1 is NH or O; g2 is preferably 1, 4; or Among them, R L1a , R L1b are independently H, -CH3, -CX3, -CHX2, -CH2X, -CN, -Ph, C 1-6 Alkyl, 2- to 6-membered alkyl or 3- to 6-membered cycloalkyl, wherein X is Cl, Br, or I;
[0082] or Among them, g3 is 0, 1, 2, 3, 4, with 1 and 2 being prioritized.
[0083] In some embodiments, L2 is an independent bond, or substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkylene, or substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted aryl.
[0084] For example, L2 may include but is not limited to the following structure: where R L2a 、R L2b are independently H, C 1-5 Alkyl chain, 3-6 membered cycloalkyl or phenyl, preferably H, methyl, ethyl, 5-6 membered cycloalkyl or phenyl; wherein h1, h2, h3 are each independently an integer between 0 and 6, preferably 0, 1 or 2;
[0085] or where R L2c 、R L2d are independently H or C 1-6 The alkyl chain, h4, h5, h6 are independently 0, 1, 2, 3, 4, 5 or 6, wherein h4 is preferably 0, 1 or 2, h5 is preferably 5 or 6, and h6 is preferably 4, 5 or 6.
[0086] or wherein h7 and h8 are independently 1, 2, 3, 4, 5 or 6, preferably 1, 2 or 3.
[0087] In Formula 1, R1 is -OH or a phosphate group. In the embodiments of the present application, "phosphate group" refers to a phosphate acyl group, i.e., a group formed by removing one or two hydrogen atoms from monophosphate or polyphosphate, and its chemical structure is shown below, wherein n is an integer selected from 1 to 3:
[0088] In Formula 1, R2 is H or a chemically cleavable group. When R2 is a chemically cleavable group, it binds to the 3' hydroxyl site of the ribose or deoxyribose sugar, inhibiting the polymerization reaction of the next nucleotide or its analog at that position, thereby allowing each polymerization reaction in step (ii) to introduce only one nucleotide or its analog into the nucleic acid chain. Furthermore, the chemically cleavable group can be reversibly removed under appropriate conditions through a chemical reaction, such as a cleavage reaction, to restore the 3' hydroxyl state of the ribose or deoxyribose sugar.
[0089] In some embodiments, R2 is selected from H, -CH2N3, -CH(N3)CH2F, -CH(N3)C(O)NHBu, -CH(N3)CHF2, -CH(N3)C(O)OH, -CH(N3)CH2O(CH2)6NH2, -CH(N3)CH2OArC(O)NH(CH2)6NH2, and -C(R 1a R1b )-OC(R 2a R 2b )R7. Wherein, R6 is selected from an alkylene group having 1 to 8 carbon atoms, and exemplary, R6 is selected from -(CH2) s -or-(CH2) s -isomers, s is selected from 1-8, specifically 1, 2, 3, 4, 5, 6, 7, 8. For example, R6 can be -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6- and the like. When R2 is selected from -C(R 1a R 1b )-OC(R 2a R 2b )R7, R 1a 、R 1b are each independently selected from H, a halogen atom, an alkyl group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a haloalkoxy group having 1 to 6 carbon atoms, a cyano group, an optionally substituted phenyl group or an optionally substituted aralkyl group, R 2a 、R 2b are each independently selected from H, a halogen atom, an alkyl group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms, a cyano group, or R 1a 、R 2a Together with the atoms to which they are attached, they form an optionally substituted five- to eight-membered alkyl or heterocyclic group; R7 is selected from H, an optionally substituted alkenyl group having 2 to 6 carbon atoms, an optionally substituted cycloalkenyl group having 3 to 7 carbon atoms, an optionally substituted alkynyl group having 2 to 6 carbon atoms, and an optionally substituted silicon-containing group.
[0090] In Formula 1, R3 is H or -OR5, wherein R5 is H or a chemically cleavable group. When R5 is a chemically cleavable group, its type can refer to R2.
[0091] In Formula 1, R4 contains the optical detection label. An optical detection label refers to a group that can generate a certain detectable light signal under light excitation, wherein the light signal includes a fluorescent signal. Exemplarily, in one example, the detectable group is a fluorescent dye. In this case, a nucleotide or an analog thereof containing a fluorescent dye can generate a detectable fluorescent signal under the action of excitation light. Exemplarily, the optical detection label includes one or more of Atto532, CY5, IF700, ROX, rhodamine dye, cyanine dye, coumarin dye, or phytochrome.
[0092] In the structure provided by the above formula 1, when the types of nucleotides or their analogs are different, their final concentrations participating in the polymerization reaction may be different. As a first embodiment, B is selected from adenine or its analogs, and in this case, the nucleotide or its analogs are adenine nucleotides or their analogs. In some embodiments, when the reaction system of the polymerization reaction in step (ii) contains adenine nucleotides or their analogs, the final concentration of adenine nucleotides or their analogs is 500nmol / L to 1000nmol / L, specifically 125nmol / L, 150nmol / L, 175nmol / L, 200nmol / L, 225nmol / L, 250nmol / L, 275nmol / L, 300nmol / L, 325nmol / L, 350nmol / L, 375nmol / L, 400nmol / L, 425nmol / L, 450nmol / L, 475nmol / L, 50 ... 5nmol / L, 500nmol / L, 525nmol / L, 550nmol / L, 575nmol / L, 600nmol / L, 625nmol / L, 650nmol / L, 675nmol / L, 700nmol / L, 725nmol / L, 750nmol / L, 775nmol / L, 800nmol / L, 825nmol / L, 850nmol / L, 875nmol / L, 900nmol / L, 925nmol / L, 950nmol / L, 975nmol / L, 1000nmol / L and other situations.
[0093] In a second embodiment, B is selected from guanine or an analog thereof, and in this case, the nucleotide or analog thereof is a guanine nucleotide or an analog thereof. In some embodiments, when the reaction system of the polymerization reaction in step (ii) contains guanine nucleotide or an analog thereof, the final concentration of the guanine nucleotide or an analog thereof is 125 nmol / L to 500 nmol / L, specifically 125 nmol / L, 150 nmol / L, 175 nmol / L, 200 nmol / L, 225 nmol / L, 250 nmol / L, 275 nmol / L, 300 nmol / L, 325 nmol / L, 350 nmol / L, 375 nmol / L, 400 nmol / L, 425 nmol / L, 450 nmol / L, 475 nmol / L, 500 nmol / L, and the like.
[0094] As a third embodiment, B is selected from cytosine or its analogs, and in this case, the nucleotide or its analogs are cytosine nucleotides or their analogs. In some embodiments, when the reaction system of the polymerization reaction in step (ii) contains cytosine nucleotides or their analogs, the final concentration of cytosine nucleotides or their analogs is 500 nmol / L to 1000 nmol / L, specifically 125 nmol / L, 150 nmol / L, 175 nmol / L, 200 nmol / L, 225 nmol / L, 250 nmol / L, 275 nmol / L, 300 nmol / L, 325 nmol / L, 350 nmol / L, 375 nmol / L, 400 nmol / L, 425 nmol / L, 450 nmol / L, 475 nmol / L, 50 ... 5nmol / L, 500nmol / L, 525nmol / L, 550nmol / L, 575nmol / L, 600nmol / L, 625nmol / L, 650nmol / L, 675nmol / L, 700nmol / L, 725nmol / L, 750nmol / L, 775nmol / L, 800nmol / L, 825nmol / L, 850nmol / L, 875nmol / L, 900nmol / L, 925nmol / L, 950nmol / L, 975nmol / L, 1000nmol / L and other situations.
[0095] As a fourth embodiment, B is selected from thymine or its analogues, in which case the nucleotide or its analogues are thymine nucleotides or their analogues; or, when B is selected from uracil nucleotides or their analogues, in which case the nucleotide or its analogues are uracil nucleotides or their analogues. In some embodiments, when the reaction system of the polymerization reaction in step (ii) contains thymine or its analogues, or when the reaction system of the polymerization reaction in step (ii) contains uracil nucleotides or their analogues, the final concentration of the nucleotide or its analogues is 500 nmol / L to 1000 nmol / L, specifically 125 nmol / L, 150 nmol / L, 175 nmol / L, 200 nmol / L, 225 nmol / L, 250 nmol / L, 275 nmol / L, 300 nmol / L, 325 nmol / L, 350 nmol / L, 375 nmol / L, 400 nmol / L, 425 nmol / L, or 500 nmol / L. L, 450nmol / L, 475nmol / L, 500nmol / L, 525nmol / L, 550nmol / L, 575nmol / L, 600nmol / L, 625nmol / L, 650nmol / L, 675nmol / L, 700nmol / L, 725nmol / L, 750nmol / L, 775nmol / L, 800nmol / L, 825nmol / L, 850nmol / L, 875nmol / L, 900nmol / L, 925nmol / L, 950nmol / L, 975nmol / L, 1000nmol / L and other situations.
[0096] In the present embodiment, four nucleotides or their analogs carrying different optically detectable labels are added simultaneously in step (ii) to bind to the nucleic acid template-primer complex. In this case, the optically detectable labels of the nucleotides or their analogs added simultaneously are different, so that when optical signal detection and imaging are performed in step (iii), the different nucleotides or their analogs bound to the nucleic acid template-primer complex can be distinguished and identified in the image or other data obtained by image processing.
[0097] In this step, nucleotides or their analogs are added in a solution, allowing them to react evenly with the nucleic acid template-primer complex. In one implementation, a mixture solution of two nucleotides or their analogs carrying different optically detectable labels is contacted with the nucleic acid template-primer complex, allowing the nucleotides or their analogs to bind to the nucleic acid template-primer complex. In this case, nucleotides or their analogs, such as four nucleotides or their analogs of ATGC or AUGC, can be combined in pairs, and each group of nucleotides or their analogs is added to participate in the polymerization reaction, allowing this group of nucleotides or their analogs to bind to the nucleic acid template-primer complex, completing a single base extension. The two nucleotides or their analogs are distinguished by the two different optically detectable labels in this group of nucleotides or their analogs. Subsequently, another group of nucleotides or their analogs is added to participate in the polymerization reaction, allowing this group of nucleotides or their analogs to bind to the nucleic acid template-primer complex, completing a second single base extension, and the two nucleotides or their analogs are distinguished by the two different optically detectable labels in this group of nucleotides or their analogs. At this point, one round of sequencing is completed. In this case, single-molecule sequencing is dual-color sequencing.
[0098] In another implementation, a mixture solution of four nucleotides or their analogs carrying different optically detectable labels is contacted with the nucleic acid template-primer complex, allowing the nucleotides or their analogs to bind to the nucleic acid template-primer complex. In this case, four nucleotides or their analogs, such as ATGC or AUGC, are added simultaneously to participate in the polymerization reaction, causing each of the four nucleotides or their analogs in the set of nucleotides or their analogs to bind to the nucleic acid template-primer complex, completing a single base extension. This completes one round of sequencing. At this point, single-molecule sequencing is four-color sequencing.
[0099] It should be understood that three nucleotides or their analogs carrying different optical detection labels can be first bound to the nucleic acid template-primer complex to achieve single-base extension; and then the remaining nucleotide or its analogue carrying one optical detection label can be bound to the nucleic acid template-primer complex to complete one round of sequencing.
[0100] It should be understood that different nucleotides or their analogs added at the same time carry different optical detection labels. In some embodiments, when the types of nucleotides or their analogs are different, the optical detection labels they carry are different. Exemplarily, in dual-color sequencing and four-color sequencing, the nucleotide or its analog is an adenine nucleotide or its analog, and the optical detection label of the nucleotide or its analog is the Atto532; the nucleotide or its analog is a guanine nucleotide or its analog, and the optical detection label of the nucleotide or its analog is the CY5; the nucleotide or its analog is a cytosine nucleotide or its analog, and the optical detection label of the nucleotide or its analog is the IF700; the nucleotide or its analog is a thymine nucleotide or its analog, and the optical detection label of the nucleotide or its analog is the ROX. At this time, the optical detection labels of different nucleotides or their analogs are more easily identified in step (iii), especially when the single-molecule sequencing is four-color sequencing, the pairing of such nucleotides and optical detection labels is conducive to improving the accuracy of base recognition.
[0101] In step (ii) of the present embodiment, "binding at least two nucleotides or their analogs carrying different optically detectable labels to the nucleic acid template-primer complex via a polymerization reaction to achieve a single-base extension and obtain an extension product" is performed in the presence of a polymerase, which is used to initiate a polymerization reaction between the nucleotides or their analogs and the terminal nucleotides or nucleotide analogs of the complementary strand of the nucleic acid template. That is, a polymerase is used to bind the nucleotides or their analogs carrying an optically detectable label to the nucleic acid template-primer complex to achieve a single-base extension. The polymerase can be a DNA polymerase or an RNA polymerase, or can contain both a DNA polymerase and an RNA polymerase. In some embodiments, the polymerase is a DNA polymerase, including but not limited to one or more of 9°N enzyme, Pfu, KOD1, and MMS2.
[0102] In some embodiments, the final concentration of the polymerase is 0.005mg / mL to 0.02mg / mL. The final concentration of the polymerase referred to in the embodiments of the present application refers to the concentration of the nucleotide or its analog when the solution containing the polymerase contacts the solid phase carrier. Exemplarily, a reaction solution containing the polymerase is introduced into the solid phase carrier, and the concentration of the polymerase in the reaction solution is the final concentration of the nucleotide or its analog. In one embodiment, this step is performed by pumping different reagents from different test kits, mixing the reagents to form a mixed solution, and flowing into the surface of the solid phase carrier. At this time, the final concentration of the polymerase should be the concentration of the polymerase in the mixed solution. The final concentration of the polymerase in the embodiments of the present application is set to 0.005mg / mL to 0.02mg / mL in order to reduce the adsorption of nucleotides or their analogs in other areas outside the solid phase carrier surface site under the polymerization reaction conditions, thereby reducing the nonspecific adsorption formed thereby. The optical detection labels in the nucleotides or their analogs at the locations of these nonspecific adsorptions are excited in step (iii) to generate optical signals, increase the background noise in the image obtained by imaging, interfere with the recognition of the optical signal at the site, and thus affect the accuracy of base recognition.
[0103] Illustratively, the final concentration of the polymerase is 0.005 mg / mL, 0.006 mg / mL, 0.007 mg / mL, 0.008 mg / mL, 0.009 mg / mL, 0.01 mg / mL, 0.011 mg / mL, 0.012 mg / mL, 0.013 mg / mL, 0.014 mg / mL, 0.015 mg / mL, 0.016 mg / mL, 0.017 mg / mL, 0.018 mg / mL, 0.019 mg / mL, 0.02 mg / mL, and the like.
[0104] In some embodiments, the polymerization reaction in step (ii) is carried out at a pH of 8.0 to 9.0. Thus, by regulating the concentration of the nucleotides or their analogs involved in the polymerization reaction, the concentration of the polymerase, and the pH of the reaction system, the adsorption of the nucleotides or their analogs to regions other than the solid support surface sites can be effectively reduced, thereby reducing the resulting nonspecific adsorption, reducing background noise in the image obtained in step (iii), and improving the accuracy of base recognition.
[0105] In the embodiment of the present application, the reaction system of the polymerization reaction in step (ii) further includes a solvent for dissolving nucleotides or their analogs and polymerase, and the solvent can be a buffer such as tris(hydroxymethyl)aminomethane buffer, glycine, ethanolamine, tetraethylethylenediamine, tetramethylethylenediamine, N-butyldiethanolamine, diethylaminoethanol, Hepes buffer, or N,N-dihydroxyethylglycine.
[0106] In step (ii), four nucleotides or their analogs are bound to the nucleic acid template-primer complex by one or two single-base extensions. At this time, the solid phase carrier carries an optical detection label at each site where the nucleic acid template-primer is bound.
[0107] (iii) Exciting the optical detection label to generate an optical signal, imaging the extension product, and obtaining an image.
[0108] In this step, the optical detection marker on the surface of the solid phase carrier after the polymerization reaction is photoexcited to generate an optical signal, such as a fluorescent signal. It should be understood that different optical detection markers require different wavelengths of excitation light to generate optical signals. In some embodiments, the optical detection markers of the nucleotides or their analogs added in step (ii) include at least a first optical detection marker and a second optical detection marker, and the excitation wavelengths of the first optical detection marker and the second optical detection marker differ by at least 50 nm to increase the difference in optical signals generated by the first optical detection marker and the second optical detection marker. The greater the difference in excitation wavelengths of the first optical detection marker and the second optical detection marker, the more obvious the difference in optical signals generated by the first optical detection marker and the second optical detection marker, and the easier it is to identify the two optical detection markers.
[0109] In this step, exciting the optical detection label to generate an optical signal includes exposing the solid phase carrier to light. In some embodiments, the exposure time is 100ms to 400ms. By controlling the exposure time, the difference in optical signal intensity generated by the optical detection label can be increased to a certain extent, thereby facilitating the identification of the type of nucleotide or its analog introduced at each site and improving the accuracy of base recognition. Exemplarily, the exposure time is 100ms, 120ms, 150ms, 180ms, 200ms, 220ms, 250ms, 280ms, 300ms, 320ms, 350ms, 380ms, 400ms and the like. It should be understood that the exposure time can be adjusted according to the type of optical detection label to achieve the purpose of increasing the difference in optical signal intensity generated by the optical detection label. In one embodiment, the first optical detection label is a red light-excitable fluorescent group, and the exposure time of the red light-excitable group is 100ms to 400ms, such as 100ms, 120ms, 150ms, 180ms, 200ms, 220ms, 250ms, 280ms, 300ms, 320ms, 350ms, 380ms, and 400ms; the second optical detection label is a green light-excitable fluorescent group, and the exposure time of the green light-excitable group is 50ms to 100ms, such as 50ms, 60ms, 70ms, 80ms, 90ms, and 100ms.
[0110] After exciting the optical detection marker to generate an optical signal, the extension product is imaged to obtain an image. By acquiring this image and analyzing the optical signal based on the image, the type of nucleotide or its analog participating in the polymerization reaction at each site is determined, thereby achieving base recognition for the current round of base extension reaction.
[0111] In some embodiments, optical imaging of the solid support can be performed before step (i) to determine the background noise on the surface of the solid support.
[0112] (iv) removing the optical detection label on the extension product.
[0113] In this step, the optical detection label on the extension product, specifically the nucleotide or its analogue bound to the end of the extension product, is removed to prevent the optical detection label on the nucleotide or its analogue bound to the end of the extension product from interfering with the optical signal of the next step (iii) when steps (i) to (iii) are repeated next time.
[0114] In some embodiments, the optically detectable label is attached to a nucleotide or its analog via a chemically cleavable group, and an excision reagent is used to remove the optically detectable label from the extension product. Exemplarily, the chemically cleavable group on the nucleotide or its analog bound to the end of the extension product is cut by passing an excision reagent onto the surface of the solid support, thereby removing the optically detectable label attached via the chemically cleavable group. Of course, it should be understood that other chemically cleavable groups on the nucleotide or its analog bound to the end of the extension product can also be cleaved by the excision reagent.
[0115] In one embodiment, the general structural formula of a nucleotide or its analogue is shown in Formula 1. In this case, when R2 is a chemically cleavable group, it can be reduced to H by a cleavage reagent, i.e., the 3' end of the pentose is reduced to a hydroxyl group. Removal of the chemically cleavable group by the cleavage reagent can restore the polymerization reactivity of the extension product, specifically the nucleotide or its analogue bound to the terminal end of the extension product.
[0116] In some embodiments, the excision reagent includes an organophosphine and a buffer. The organophosphine acts as a reducing agent to reduce the chemically cleavable group, thereby causing the chemically cleavable group to fall off the extension product, preparing for the next single-base extension. This preparation includes: on the one hand, reducing the chemically cleavable group on the pentose to a hydroxyl group, providing a reaction site for the binding of a nucleotide or its analog for the next polymerization reaction; on the other hand, reducing the azidooxymethyl group attached to one side of B, thereby excising the -O-CH(N3)-L2-R4 attached to the azidooxymethyl group, eliminating the inhibition of the group on the polymerization reaction site on the pentose.
[0117] The organic phosphine used to reduce the azidomethoxy group is selected from at least one trivalent organic phosphine. In some embodiments, the organic phosphine is selected from at least one of tris(3-hydroxypropyl)phosphine, tris(2-carboxyethyl)phosphine, trishydroxymethylphosphine, triphenylphosphine, and tris(2-hydroxyethyl)phosphine. In some embodiments, the concentration of the organic phosphine is 10 mmol / L to 100 mmol / L. Specifically, the concentration of the organic phosphine can be 10 mmol / L, 15 mmol / L, 20 mmol / L, 25 mmol / L, 30 mmol / L, 35 mmol / L, 40 mmol / L, 45 mmol / L, 50 mmol / L, 55 mmol / L, 60 mmol / L, 65 mmol / L, 70 mmol / L, 75 mmol / L, 80 mmol / L, 85 mmol / L, 90 mmol / L, 95 mmol / L, 100 mmol / L, and the like.
[0118] In some embodiments, the buffer is selected from at least one of a primary amine buffer and a tertiary amine buffer. These buffers can serve as solvents for the reaction materials of the mixed reaction and can provide a stable pH environment. Compared to primary amine buffers, tertiary amine buffers can provide a more stable reaction environment for the reduction of azidomethoxy groups to hydroxyl groups. Exemplarily, the buffer is selected from at least one of tris buffer, glycine, ethanolamine, tetraethylethylenediamine, tetramethylethylenediamine, N-butyldiethanolamine, diethylaminoethanol, Hepes buffer, and N,N-bicine.
[0119] In some embodiments, the concentration of the buffer is 0.01mol / L to 2mol / L. The pH environment provided when the concentration of the buffer is 0.01mol / L to 2mol / L is conducive to improving the uniformity and stability of the reduction reaction. Exemplarily, the concentration of the buffer in the mixed solution is 10mmol / L, 15mmol / L, 20mmol / L, 25mmol / L, 30mmol / L, 35mmol / L, 40mmol / L, 45mmol / L, 50mmol / L, 55mmol / L, 60mmol / L, 65mmol / L, 70mmol / L, 75mmol / L, 80mmol / L, 85mmol / L, 90mmol / L, 95mmol / L, 100mmol / L, 105mmol / L, 110mmol / L, 115mmol / L, 120mmol / L, 125mmol / L, 130mmol / L, 135mmol / L, 140mmol l / L, 145mmol / L, 150mmol / L, 155mmol / L, 160mmol / L, 165mmol / L, 170mmol / L, 175mmol / L, 180mmol / L, 0.2mol / L, 0.3mol / L, 0.4mol / L, 0.5mol / L, 0.6mol / L, 0 .7mol / L, 0.8mol / L, 0.9mol / L, 1.0mol / L, 1.1mol / L, 1.2mol / L, 1.3mol / L, 1.4mol / L, 1.5mol / L, 1.6mol / L, 1.7mol / L, 1.8mol / L, 1.9mol / L, 2.0mol / L and other specific situations.
[0120] In some embodiments, the removal of optically detectable labels on the extension products is performed at a pH of 8.0 to 10.5 and a temperature of 39°C to 65°C. At a pH of 8.0 to 10.5 and a reaction temperature of 39°C to 65°C, the structure of the nucleic acid chain is stable, and this temperature can also provide good reduction efficiency for the chemical cleavage group. Exemplary, the reaction temperature of the excision reagent can be 39°C, 40°C, 42°C, 45°C, 48°C, 50°C, 53°C, 55°C, 57°C, 60°C, 62°C, 65°C, and the like. Exemplarily, the pH value of the excision reagent is 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, and the like.
[0121] The embodiment of the present application further comprises, after step (iv), a cleaning treatment using a cleaning reagent to remove the excision reagent to avoid residual organophosphine. If organophosphine remains in steps (i)-(iii) of the current single base extension, then during the next single base extension, the organophosphine may reduce the optical cleavage group and -O-CH(N3)- of the nucleotide or its analogue, resulting in the single extension reaction not being terminated, thereby failing to effectively control the number of nucleotides or their analogues incorporated into the nucleic acid template-primer complex, resulting in prephasing (or prephase, which refers to the nucleotides or their analogues introduced in the next or subsequent base extensions undergoing polymerization in advance during the current base extension and binding to the complementary chain of the nucleic acid template during sequencing), thereby failing to accurately identify the nucleic acid sequence of the introduced nucleotide region; or during the new base extension reaction, before the extension product after the introduction of the nucleotide or its analogue has time to be imaged, the organophosphine has already optically cleaved the group, resulting in the optical detection label falling off, and failing to identify the type of nucleotide or its analogue introduced in the current single base extension reaction.
[0122] On the other hand, the principle of selecting the connecting group between the side chain and 3'-OH. The group used in the embodiment is azide, which is a cleavable group. However, in practical applications, it is not limited to this group and other cleavable blocking groups can be tried. According to the several groups shown in EP3388442A1: -CH2F, -C(O)NHBu, -CHF2, -C(O)OH, -CHF2, -C6, -ArC6, these groups can be cleaved by the reducing reagent tris(hydroxymethyl)phosphine. In addition, acetal can also be used as a blocking group, but the cleavage of this group requires the use of a palladium catalyst, and the excision reagent provided in this patent cannot effectively cleave the acetal group. The group connecting the side chain to the 3'-OH can be the same group as shown in the patent, or different groups can be selected. However, in the case of different groups, the selected groups are required to be effectively cleaved by the same reagent at the same time, and the 3' end is in a hydroxyl state after the blocking group is cleaved.
[0123] The present invention is further described below using four-color sequencing as an example.
[0124] The four nucleotides used for sequencing in the embodiment of the present invention are represented as follows: dATP-N3-Atto532, dTTP-N3-ROX, dCTP-N3-IF700 and dGTP-N3-CY5, and their general structural formulas are as follows:
[0125] Wherein, B is A, T, G, or C, L1 and L2 are each independently a covalent bond or a covalent linking group, R4 contains Atto532, ROX, IF700, or CY5, and n is an integer selected from 1 to 3. The excitation wavelength and emission wavelength of Atto532, ROX, IF700, or CY5 are shown in Table 1 below.
[0126] Table 1
[0127] Example 1 Adsorption test of single molecule four-color sequencing
[0128] On single-molecule sequencing platforms, nonspecific adsorption of nucleotides or their analogs on the solid support surface can significantly interfere with base signal recognition during sequencing, impacting sequencing quality. Therefore, adsorption testing can be performed to determine the appropriate concentrations of the four nucleotides and polymerase during the base extension reaction for the nucleotides or their analogs used in the sequencing reaction.
[0129] The adsorption test method is as follows:
[0130] Providing a surface-treated solid support, the solid support comprising a plurality of sites, each site having the ability to immobilize a nucleic acid template-primer complex, but not immobilizing the nucleic acid template-primer complex;
[0131] Nucleotide solutions of dATP-N3-Atto532, dTTP-N3-ROX, dCTP-N3-IF700, and dGTP-N3-CY5 were prepared separately. 9°N enzyme was added to each nucleotide solution to form an extension reagent. The extension reagent containing dATP-N3-Atto532 and 9°N enzyme was named dATP-N3-Atto532 extension reagent, the extension reagent containing dTTP-N3-ROX and 9°N enzyme was named dTTP-N3-ROX extension reagent, the extension reagent containing dCTP-N3-IF700 and 9°N enzyme was named dCTP-N3-IF700 extension reagent, and the extension reagent containing dGTP-N3-CY5 and 9°N enzyme was named dGTP-N3-CY5 extension reagent. Different nucleotide concentrations and 9°N enzyme concentrations were set in each extension reagent.
[0132] The surface of the solid support is treated with excitation light having the same excitation wavelength as the fluorescent group carried by the extension reagent to be added, and the solid support after the excitation treatment is imaged to obtain a first image; each extension reagent is added to the surface of the solid support, and the fluorescent group on each extension reagent is excited to generate an optical signal, and the solid support is imaged to obtain an image;
[0133] The images were analyzed and the average number of fluorescence signal points (adsorption points) in the images was counted. The results are shown in Table 2 below.
[0134] Table 2
[0135] As shown in Table 2, when the concentrations of dATP-N3-Atto532, dTTP-N3-ROX, and dCTP-N3-IF700 range from 500 nmol / L to 1000 nmol / L, the concentration of the nucleotide solution of dGTP-N3-CY5 ranges from 125 nmol / L to 500 nmol / L, and the concentration of 9°N is 0.01 mg / mL, the number of adsorption sites is less than 500. The adsorption ratio on the solid support surface is calculated as (number of adsorption sites / total number of sites on the support surface) × 100%. An adsorption ratio below 2% is beneficial for improving base call accuracy and ultimately sequencing quality.
[0136] Example 2 Single-molecule four-color sequencing
[0137] The method for single-molecule four-color sequencing is as follows:
[0138] Providing a surface-treated solid phase support, the solid phase support comprising a plurality of sites, each site having an immobilized nucleic acid template-primer complex;
[0139] A nucleotide solution containing 500 nmol / L dATP-N3-Atto532, 500 nmol / L dTTP-N3-ROX, 1000 nmol / L dCTP-N3-IF700, and 125 nmol / L dGTP-N3-CY5 was prepared, and 9°N enzyme was added to a concentration of 0.01 mg / mL to form an extension reagent. The extension reagent containing dTTP-N3-ROX and 9°N enzyme was designated dTTP-N3-ROX extension reagent, the extension reagent containing dCTP-N3-IF700 and 9°N enzyme was designated dCTP-N3-IF700 extension reagent, and the extension reagent containing dGTP-N3-CY5 and 9°N enzyme was designated dGTP-N3-CY5 extension reagent. Different nucleotide and 9°N enzyme concentrations were set in each extension reagent.
[0140] An extension reagent is added to the surface of the solid phase carrier, and 532nm laser and 640nm laser excitation light are used to irradiate the surface of the solid phase carrier and excite the fluorescent group on the extension reagent to generate an optical signal, and the solid phase carrier is imaged and the image is collected.
[0141] Due to image clarity and the inherent limitations of single molecules, multi-color sequencing algorithms have difficulty distinguishing different types of nucleotide images, particularly GC images. In this example, four exposure times of 50ms, 100ms, 200ms, and 400ms were set for a 640nm laser, and the brightness differences between dCTP-N3-IF700 and dGTP-N3-CY5 were observed. The results are shown in Figure 1. As can be seen, when the exposure time is 50ms, the fluorescence intensities of dCTP-N3-IF700 and dGTP-N3-CY5 are similar; as the exposure time increases, the difference in fluorescence intensity between dCTP-N3-IF700 and dGTP-N3-CY5 increases. For a 640nm laser, exposure times of 100ms or longer can better distinguish GC images. Increasing the exposure time can increase the fluorescence brightness differences between multiple nucleotides, such as GC, within the same fluorescence channel in multi-color sequencing. Specifically, as shown in Figure 2, the fluorescence image formed by dCTP-N3-IF700 alone (dCTP-N3-IF700 in single-color sequencing) with a 640nm laser exposure time of 50ms is shown in the left figure of Figure 2, while the GC fluorescence image collected after the addition of four nucleotides is shown in the right figure of Figure 2. As can be seen from the figure, after the G is strung to the C image, it is difficult to distinguish the GC points in the C image by brightness. This embodiment adjusts the exposure time, such as adjusting the exposure time of the red light excitation group to 100ms-400ms and the green light excitation group to 50ms-100ms, to distinguish images that are difficult for the algorithm to distinguish.
[0142] We used 532nm and 640nm lasers to verify different exposure times for 40-cycle base extension. We analyzed the effects of four different exposure conditions on the 40-cycle read length distribution: 532nm exposure for 80ms and 640nm exposure for 400ms, 532nm exposure for 100ms and 640nm exposure for 400ms, 532nm exposure for 80ms and 640nm exposure for 200ms, and 532nm exposure for 60ms and 640nm exposure for 200ms. The results are shown in Figure 3. Figure 3 shows that exposure time affects sequencing read length. Specifically, increasing exposure time increases photodamage, resulting in shorter read lengths. Therefore, shorter exposure times were selected based on the algorithm's ability to distinguish between the two.
[0143] A 50-cycle base extension was performed using a 532 nm laser with an exposure time of 80 ms, and a 640 nm laser with exposure times of 150 ms and 200 ms, respectively. The sequencing data is shown in Table 3 below (the number of reads uniquely aligned to the genome refers to the number of reads uniquely aligned to the reference genome within the central 1024×1024 pixel area of a field of view (FOV). Error rate = mismatch rate + deletion error rate + insertion error rate. As can be seen, the sequencing data obtained from 50-cycle base extension with exposure times of 150 ms and 200 ms are not significantly different. The distribution of 50-cycle read lengths under different exposure times is shown in Figure 4, showing no significant difference in read length distribution between exposure times of 150 ms and 200 ms. Combined with the long sequencing results, when the 532 laser is 80ms and the 640 laser is 150ms, dCTP-N3-IF700 and dGTP-N3-CY5 can be distinguished by brightness, with minimal impact on read length. Ultimately, the main peak of the 50-cycle sequencing read length distribution is around 50bp, with an error rate of 7% to 8%, enabling four-color sequencing on a single-molecule sequencing platform. Therefore, to save sequencing time, a 150ms exposure time can be considered for subsequent 640nm lasers.
[0144] Table 3
[0145] Example 3 Single-molecule four-color sequencing
[0146] The method for single-molecule four-color sequencing is as follows:
[0147] Providing a surface-treated solid phase support, the solid phase support comprising a plurality of sites, each site having an immobilized nucleic acid template-primer complex;
[0148] A nucleotide solution containing 500 nmol / L dATP-N3-Atto532, 500 nmol / L dTTP-N3-ROX, 1000 nmol / L dCTP-N3-IF700, and 125 nmol / L dGTP-N3-CY5 was prepared, and 9°N enzyme was added to a concentration of 0.01 mg / mL to form an extension reagent. The extension reagent containing dATP-N3-Atto532 and 9°N enzyme was designated dATP-N3-Atto532 extension reagent, the extension reagent containing dTTP-N3-ROX and 9°N enzyme was designated dTTP-N3-ROX extension reagent, the extension reagent containing dCTP-N3-IF700 and 9°N enzyme was designated dCTP-N3-IF700 extension reagent, and the extension reagent containing dGTP-N3-CY5 and 9°N enzyme was designated dGTP-N3-CY5 extension reagent. Different nucleotide concentrations and 9°N enzyme concentrations were set in each extension reagent;
[0149] An extension reagent is added to the surface of the solid phase carrier, and the 532 laser and 640 laser excitation light are used to irradiate the surface of the solid phase carrier and excite the fluorescent group on the extension reagent to generate an optical signal, and the solid phase carrier is imaged and the image is collected.
[0150] A Tris buffer system containing THPP was prepared as an excision reagent, and various excision reagents were added to the surface of the solid support to perform an excision reaction on the azidomethoxy group. The excision percentage of the azidomethoxy group on the surface of the solid support was calculated (the number of optical signal points before and after excision was calculated; the excision percentage of the azidomethoxy group = (the number of optical signal points before excision - the number of optical signal points after excision) / the number of optical signal points before excision × 100%), or the residual percentage of the azidomethoxy group on the surface of the solid support was calculated (the number of optical signal points before and after excision was calculated; the residual percentage of the azidomethoxy group = the number of optical signal points after excision / the number of optical signal points before excision × 100%).
[0151] (1) In the excision reagent, the concentration of Tris was 2.0 mol / L, and four concentrations of THPP were set: 10 mmol / L, 25 mmmol / L, 50 mmol / L, and 100 mmol / L. The statistics of the optical signals before and after the excision reaction under the four concentration conditions are shown in Figure 5. The calculation results show that the excision percentages under the four concentration conditions are 67.79%, 63.92%, 68.87%, and 68.67%, respectively. It can be seen that increasing the THPP concentration has no obvious effect on improving the excision efficiency.
[0152] (2) In the excision reagent, the concentration of THPP was 10.0 mmol / L, and the Tris buffer was set to four concentrations: 0.01 mol / L, 0.2 mol / L, 1 mol / L, and 2 mol / L. The optical signal statistics before and after the excision reaction under the four concentration conditions are shown in Figure 6. Figure 6 shows that the residual percentages after the excision reaction under the four concentration conditions were 32.66%, 3.46%, 1.93%, and 0.48%, respectively. It can be seen that the concentration of Tris buffer affects the removal of azidomethoxy groups, thereby affecting the sequencing error rate. When the concentration of Tris buffer is 0.2 mol / L to 2.0 mol / L, the residual percentage of azidomethoxy groups is lower.
[0153] (3) In the excision reagent, under the conditions of a Tris concentration of 2.0 mol / L and a THPP concentration of 10.0 mmol / L, the pH was set to 8.0, 9.0, and 10.3. The optical signal statistics before and after the excision reaction under the three pH conditions are shown in Figure 7. Figure 7 shows that the residual percentages after the excision reaction under the three pH conditions were 13.93%, 2.95%, and 1.50%, respectively. It can be seen that pH affects the removal of azidomethoxy groups, thereby affecting the sequencing error rate. When the pH is 9 or above, the residual percentage of azidomethoxy groups is lower. Considering that too high pH affects the stability of nucleic acid molecules, the pH value of 9 to 10.3 is appropriate for four-color sequencing.
[0154] (4) In the step of performing the excision reaction on the azidomethoxy group, an excision reagent with a concentration of 2.0 mol / L Tris, a concentration of 10.0 mmol / L THPP, and a pH value of 9.0 was used. The excision reaction was performed at temperatures of 39°C, 57°C, 61°C, and 65°C, respectively. The optical signal statistics before and after the excision reaction under the four temperature conditions are shown in FIG8 . FIG7 shows that the residual percentages after the excision reaction under the four temperature conditions were 15.79%, 4.50%, 2.71%, and 2.64%, respectively. It can be seen that temperature affects the removal of the azidomethoxy group, thereby affecting the sequencing error rate. When the temperature is 39°C or above, the residual percentage of the azidomethoxy group is lower. Considering that excessively high temperature affects the stability of nucleic acid molecules, the temperature for four-color sequencing is preferably 39°C to 65°C.
[0155] The excision reagent was optimized through THPP concentration gradient, Tris concentration gradient, pH gradient and temperature gradient. Among them, the increase of Tris concentration can significantly reduce the residual after excision. Under the condition of high concentration of Tris of 2 mol / L, the increase of pH and temperature is also conducive to further reducing the residual after excision. The final THPP excision efficiency is above 95%.
[0156] Example 4 Single-molecule four-color sequencing
[0157] The method includes:
[0158] (1) providing a surface-treated solid support, the solid support comprising a plurality of sites, each site having a fixed nucleic acid template-primer complex;
[0159] (2) Prepare a nucleotide solution of 500 nmol / L dATP-N3-Atto532, 500 nmol / L dTTP-N3-ROX, 1000 nmol / L dCTP-N3-IF700, and 125 nmol / L dGTP-N3-CY5 (buffer: 50 mmol / L Tris-Base pH 8.8, 50 mmol / L NaCl, 10 mmol / L (NH4)2SO4, 3 mmol / L MgSO4), and add 9°N enzyme to a concentration of 0.01 mg / mL to form an extension reagent;
[0160] (3) adding an extension reagent to the surface of the solid support, irradiating the surface of the solid support with 532 laser and 640 laser excitation light for 80 m and 150 ms, respectively, imaging the solid support and collecting images;
[0161] (4) Prepare an excision reagent containing the following ingredients: 2 mol / L Tris-Base, 1 mol / L sodium chloride, 10 mmol / L THPP, 0.05% Tween 20, pH 9.0, add the excision reagent to the surface of the solid phase support, and perform an excision reaction on the azidomethoxy group.
[0162] Repeat the above steps (1)-(4) 50 times, i.e., sequence 50 cycles. The read length distribution of 50 cycles is shown in FIG9 . It can be seen from the figure that the main peak of the 50-cycle sequencing read length distribution is around 50 bp, and the proportion of sequencing terminated before 45 cycles is relatively small.
[0163] The error rate for 50 cycles was calculated, and the results are shown in Table 4 below. The number of reads uniquely aligned to the genome refers to the number of reads uniquely aligned to the reference genome within a 1024×1024 pixel area in the center of a field of view (FOV). The error rate (error rate = mismatch rate + deletion error rate + insertion error rate) was approximately 6%.
[0164] Table 4
[0165] The error statistics for four-color sequencing are shown in Figure 10, where Ins_N represents an insertion error of type N, Del_N represents a deletion error of type N, and N1->N2 indicates an error in which N1 was mistakenly identified as N2. N, N1, and N2 each represent one of A, T, G, and C. Figure 10 shows that the error types and their distribution ratios for 50 cycles of four-color sequencing are within the acceptable range for single-molecule sequencing.
[0166] The reaction efficiency was high when dG-Atto647N replaced dG-CY5. The error rate statistics are shown in Table 4. The error rate after dG-Atto647N replacement was similar, but the flux was slightly higher. It can be used as a substitute for dG-CY5.
[0167] In summary, four-color sequencing can be achieved on a single-molecule platform with good accuracy and long read length.
[0168] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.
Claims
1. A single molecule sequencing method, characterized in that: The steps include: (i) providing a solid phase carrier, wherein the solid phase carrier comprises a plurality of sites, each of which is fixed with a nucleic acid template-primer complex; (ii) binding four nucleotides or their analogs carrying different optical detection labels to the nucleic acid template-primer complex through a polymerization reaction to achieve single base extension and obtain an extension product; (iii) exciting the optical detection label to generate an optical signal, imaging the extension product, and obtaining an image; (iv) removing the optical detection label on the extension product; (v) replacing the nucleic acid template-primer complex with the extension product from which the optically detectable label has been cleaved, and repeating the above steps (ii) to (iv) one or more times to determine the template nucleic acid sequence.
2. The sequencing method according to claim 1, characterized in that In step (ii), a mixture solution of two or four nucleotides or their analogs carrying different optical detection labels is contacted with the nucleic acid template-primer complex to allow the nucleotides or their analogs to bind to the nucleic acid template-primer complex.
3. The sequencing method according to claim 2, characterized in that In step (ii), the final concentrations of the four nucleotides or their analogs are 125 nmol / L to 1000 nmol / L, respectively.
4. The sequencing method according to any one of claims 1 to 3, characterized in that The general formula of the nucleotide or its analogue is shown in Formula 1: Wherein, B is a base or its analogue, L1 and L2 are each independently a covalent bond or a covalent linking group, R1 is -OH or a phosphate group, R2 is H or a chemically cleavable group, R3 is H or -OR5, R5 is H or a chemically cleavable group, and R4 contains the optical detection label.
5. The sequencing method according to claim 4, characterized in that The B is selected from adenine or an analog thereof, guanine or an analog thereof, cytosine or an analog thereof, thymine or an analog thereof, or uracil or an analog thereof.
6. The sequencing method according to claim 4, characterized in that In step (ii), the B is selected from adenine or its analog, cytosine or its analog, thymine or its analog or uracil or its analog, and the final concentration of each nucleotide or its analog is 500nmol / L to 1000nmol / L; the B is guanine or its analog, and the final concentration of the nucleotide or its analog is 125nmol / L to 500nmol / L.
7. The sequencing method according to any one of claims 1 to 6, characterized in that: Different nucleotides or their analogs carry different optically detectable labels.
8. The sequencing method according to claim 7, characterized in that The optical detection label includes one or more of Atto532, CY5, IF700, ROX, rhodamine dye, cyanine dye, coumarin dye or phycoerythrin.
9. The sequencing method according to claim 7, characterized in that: The nucleotide or its analogue is an adenine nucleotide or its analogue, and the optical detection marker of the nucleotide or its analogue is the Atto532; the nucleotide or its analogue is a guanine nucleotide or its analogue, and the optical detection marker of the nucleotide or its analogue is the CY5; the nucleotide or its analogue is a cytosine nucleotide or its analogue, and the optical detection marker of the nucleotide or its analogue is the IF700; the nucleotide or its analogue is a thymine nucleotide or its analogue, and the optical detection marker of the nucleotide or its analogue is the ROX.
10. The sequencing method according to any one of claims 1 to 9, characterized in that: In step (ii), four nucleotides or their analogs carrying optical detection labels are bound to the nucleic acid template-primer complex using a polymerase to achieve single base extension; wherein the polymerase is a DNA polymerase and / or an RNA polymerase, and the final concentration of the polymerase is 0.005 mg / mL to 0.02 mg / mL.
11. The sequencing method according to claim 10, characterized in that: The polymerase includes one or more of 9°N enzyme, Pfu, KOD1 and MMS2.
12. The sequencing method according to any one of claims 1 to 11, characterized in that: In step (ii), the polymerization reaction is carried out at a pH of 8.0 to 9.
0.
13. The sequencing method according to any one of claims 1 to 12, characterized in that: The optical detection label is connected to the nucleotide or its analog via a chemically cleavable group. In step (iv), the removal of the optical detection label on the extension product is achieved by using an excision reagent, which includes an organic phosphine and a buffer.
14. The sequencing method according to claim 13, characterized in that: The removal of the optical detection label on the extension product is carried out at a pH value of 8.0 to 10.5 and a temperature of 39° C. to 65° C.
15. The sequencing method according to claim 13, wherein: The concentration of the organic phosphine is 10 mmol / L to 100 mmol / L; and / or the concentration of the buffer solution is 0.01 mol / L to 2.0 mol / L.
16. The sequencing method according to claim 13, characterized in that: The organic phosphine is selected from tris(3-hydroxypropyl)phosphine, tris(2-carboxyethyl)phosphine, trishydroxymethylphosphine, triphenylphosphine, and tris(2-hydroxyethyl)phosphine.
17. The sequencing method according to any one of claims 1 to 16, characterized in that: In step (iii), exciting the optical detection label to generate an optical signal comprises exposing the solid phase carrier to light, wherein the exposure time is 100 ms to 400 ms.
18. The sequencing method according to any one of claims 1 to 17, characterized in that: The optical detection mark includes a first optical detection mark and a second optical detection mark, and the excitation wavelengths of the first optical detection mark and the second optical detection mark differ by at least 50 nm.
19. The sequencing method according to claim 18, characterized in that: The first optical detection marker is a red light excitable fluorescent group, and the exposure time of the red light excitable group is 100ms to 400ms; the second optical detection marker is a green light excitable fluorescent group, and the exposure time of the green light excitable group is 50ms to 100ms.
Citation Information
Patent Citations
Modified nucleosides or nucleotides
EP3388442A1
Flourescence energy transfer-based single molecule / ensemble DNA sequencing by synthesis
CN109562376A
Stepwise sequencing by non-labeled reversible terminators or natural nucleotides
CN110418847A
Nucleotide analogues and use thereof for nucleic acid sequencing and analysis
CN112218640A
Gene sequencing method
CN114958995A
